Related Experiment Videos
Vindesine in bronchogenic carcinoma: a phase II trial
American Journal of Clinical Oncology
|February 1, 1982
Summary
Vindesine showed some activity in advanced lung cancer patients, with mild to moderate side effects. Pre-treatment with methylprednisolone helped prevent injection site reactions.
Area of Science:
- Oncology
- Pharmacology
Background:
- Advanced bronchogenic carcinoma presents significant treatment challenges.
- Evaluating novel chemotherapeutic agents is crucial for improving patient outcomes.
Purpose of the Study:
- To assess the efficacy and safety of vindesine in patients with advanced lung cancer.
- To determine response rates, duration of response, and toxicity profile of vindesine therapy.
Main Methods:
- A prospective study involving 27 patients with advanced bronchogenic carcinoma.
- Vindesine administered at a dose of 3 mg/m2 weekly.
- Evaluation of patient response, duration of response, and adverse events.
Main Results:
- Partial responses observed in 2/6 small-cell carcinoma and 1/17 non-small-cell carcinoma patients.
- Minor responses seen in 2 additional non-small-cell carcinoma patients.
- Neurologic toxicity in 14 patients (mostly mild), with significant phlebitis/cellulitis in 7, preventable with methylprednisolone.
Conclusions:
- Vindesine demonstrates activity in previously treated advanced bronchogenic carcinoma.
- The drug is generally well-tolerated, with manageable side effects.
- Methylprednisolone can mitigate local administration site toxicity.